About The Study: In this study of 69,000 adults with hepatitis C virus (HCV) infection, there was no difference in sustained virologic response across alcohol use categories, even for patients with high-risk consumption or alcohol use disorder, after adjusting for potential confounding variables. These findings suggest that restricting access to direct-acting antiviral therapy on the basis of alcohol use creates an unnecessary barrier for patients and challenges HCV elimination goals.
Authors: Emily J. Cartwright, M.D., of the Emory University School of Medicine in Atlanta, and Christopher T. Rentsch, Ph.D., of the London School of Hygiene & Tropical Medicine in London, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi: 10.1001/jamanetworkopen.2023.35715)
